The largest database of trusted experimental protocols

Atresia

Atresia refers to the complete closure or absence of a normal body opening or passage.
It can occur in various parts of the body, such as the esophagus, anus, or bile ducts.
Atresia is a congenital condition, meaning it is present at birth, and can have serious medical consequences if left untreated.
Understanding the mechanisms and characteristics of atresia is crucial for developing effective diagnostic and treatment strategies to improve patient outcomes.
PubCompare.ai, the leading AI platform, can optimze your atresia research by helping you easily locate the best protocols from literture, pre-pints, and patents using AI-driven comparisons to enhance reproducibility and accuaracy.
PubCompare.ai is your go-to tool for streamlining your atresia research process.

Most cited protocols related to «Atresia»

Infants were randomly assigned to either the MBT shunt or the RVPA shunt within strata according to the presence or absence of aortic atresia and obstructed pulmonary venous return, with dynamic allocation by the surgeon.23 (link) The primary outcome was the rate of death or cardiac transplantation 12 months after randomization. Secondary outcomes included morbidity during the Norwood and stage II hospitalizations; the incidence of unintended cardiovascular interventions involving the shunt, pulmonary arteries, or neoaorta by 12 months; right ventricular function, right ventricular volume, and the degree of tricuspid-valve regurgitation at discharge after the Norwood procedure, before stage II, and at the age of 14 months on the basis of echocardiograms interpreted by the core laboratory; and the core laboratory interpretation of pulmonary-artery size by angiography before stage II. The right ventricular volumes and ejection fractions were calculated with the use of the biplane pyramidal method.24 (link)
Safety during the first 12 months after randomization was monitored with the use of three measurements: the rate of composite serious adverse events (death, acute shunt failure, cardiac arrest, extracorporeal membrane oxygenation, unplanned cardiovascular reoperation, or necrotizing enterocolitis), the rate of composite serious adverse events with death excluded, and the rate of other complications. The prespecified subgroups for analysis were as follows: birth weight (<2500 or ≥2500 g), preoperative tricuspid-valve regurgitation (proximal jet width, <2.5 or ≥2.5 mm), deep hypothermic circulatory arrest versus regional cerebral perfusion, the surgeon’s annual experience in performing Norwood procedures in infants randomly assigned to this procedure (<6, 6 to 10, 11 to 15, or >15 procedures), and the annual volume of Norwood procedures at each center (<11, 11 to 25, 26 to 40, or >40 procedures). The protocol was approved by each center’s institutional review board, and written informed consent was obtained from a parent or guardian.
Publication 2010
Angiography Aorta atresia Birth Weight Cardiac Arrest Cardiovascular System Circulatory Arrest, Deep Hypothermia Induced Echocardiography Ethics Committees, Research Extracorporeal Membrane Oxygenation Heart Transplantation Hospitalization Infant Legal Guardians Necrotizing Enterocolitis Norwood Procedures Parent Patient Discharge Perfusion Pulmonary Artery Repeat Surgery Safety Surgeons Tricuspid Valve Insufficiency Veins, Pulmonary Ventricles, Right Ventricular Function, Right

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Study population. We used information available in the publically accessible Colorado Oil and Gas Information System (COGIS) to build a geocoded data set with latitude, longitude, and year of development (1996–2009) for all gas wells in rural Colorado (COGIS 2011 ). Live birth data were obtained from the Colorado Vital Birth Statistics (CDPHE, Denver, CO). Geocoded maternal addresses at time of birth were linked to the well locations. Distance of each maternal residence from all existing (not abandoned) natural gas wells within a 10-mile radius was then computed using spherically adjusted straight line distances. We conducted our analysis on the final de-identified database containing maternal and birth outcome data described below and distance to all wells within the 10-mile radius. The Colorado Multiple Institutional Review Board reviewed and approved our study protocol. Informed consent was not required.
We restricted analysis to births occurring from 1996 through 2009 to focus our analysis on growth of unconventional NGD, characterized by use of hydraulic fracturing and/or directional drilling (King 2012 ), which expanded rapidly in Colorado beginning around 2000 (COGIS 2011 ). We also restricted our analysis to rural areas and towns with populations of < 50,000 (excluding the Denver metropolitan area, El Paso County, and the cities of Fort Collins, Boulder, Pueblo, Grand Junction, and Greeley) in 57 counties to reduce potential for exposure to other pollution sources, such as traffic, congestion, and industry. The final study area included locations with and without NGD. We conducted a retrospective study on the resulting cohort of 124,842 live births to explore associations between birth outcomes and exposure to NGD operations. We restricted eligibility to singleton births and excluded the small proportion (< 5%) of nonwhite births because there were too few to analyze separately.
Birth outcomes. Identified birth outcomes were a) oral cleft, including cleft lip with and without cleft palate as well as cleft palate [International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 749.xx] (National Center for Health Statistics 2011 ); b) NTD, including anencephalus, spina bifida without anecephaly, and encephalocele (ICD-9-CM 740.xx, 741.xx, and 742.0); c) CHD, including transposition of great vessels, tetralogy of Fallot, ventricular septal defect, endocardial cushion defect, pulmonary valve atresia and stenosis, tricuspid valve atresia and stenosis, Ebstein’s anomaly, aortic valve stenosis, hypoplastic left heart syndrome, patent ductus arteriosis, coarctation of aorta, and pulmonary artery anomalies (codes 745.xx, 746.xx, 747.xx, excluding 746.9, 747.5); d) preterm birth (< 37 weeks completed gestation); e) term low birth weight (≥ 37 weeks completed gestation and birth weight < 2,500 g); and f) term birth weight as a continuous measure. Births with an oral cleft, NTD, or CHD were excluded from preterm birth and term low birth weight analysis. Preterm births were excluded from term birth weight analysis. Oral cleft, CHD, and NTD cases in the Colorado Responds to Children with Special Needs (CRCSN) birth registry, obtained from hospital records, the Newborn Genetics Screening Program, the Newborn Hearing Screening Program, laboratories, physicians, and genetic, developmental, and other specialty clinics (CRCSN 2011 ) were matched with Colorado live birth certificates. Cases are reflective of reporting as of 12 July 2012, were not necessarily confirmed by medical record review, and are subject to change as CRCSN ascertains diagnosis up to 3 years of child’s age and/or supplements information by medical record review. We analyzed birth defects in three heterogeneous groups to increase statistical power. Data set information was not sufficient to distinguish between multiple and isolated birth anomalies or to identify chromosomal birth anomalies. In an exploratory analysis, we considered seven clinical diagnostic groupings of CHDs: a) conotruncal defects (tetralogy of Fallot and transposition of great vessels); b) endocardial cushion and mitrovalve defects (EMD; endocardial cushion defect and hypoplastic left heart syndrome); c) pulmonary artery and valve defects (PAV; pulmonary valve atresia and stenosis and pulmonary artery anomalies); d) tricuspid valve defects (TVD; tricuspid valve atresia and stenosis and Ebstein’s anomaly); e) aortic artery and valve defects (aortic valve stenosis and coarctation of aorta); f) ventricular septal defects (VSD); and g) patent ductus arteriosis in births > 2,500 g (Gilboa et al. 2005 (link)).
Exposure assessment. Distribution of the wells within a 10-mile radius of maternal residence shows 50% and 90% of wells to be within 2.3 and 7.7 miles of maternal residence, respectively. We used an inverse distance weighted (IDW) approach, commonly used to estimate individual air pollutant exposures from multiple fixed locations (Brauer et al. 1998; Ghosh et al. 2012 (link)), to estimate maternal exposure. Our IDW well count accounts for the number of wells within the 10-mile radius of the maternal residence, as well as distance of each well from the maternal residence, giving greater weight to wells closest to the maternal residence. For example, an IDW well count of 125 wells/mile could be computed from 125 wells each located 1 mile from the maternal residence or 25 wells each located 0.2 miles from the maternal residence. We calculated the IDW well count of all existing natural gas wells in the birth year within a 10-mile radius of each maternal residence as a continuous exposure metric:
where IDW well count is the IDW count of existing wells within a 10-mile radius of maternal residence in the birth year; di is the distance of the ith individual well from maternal residence; and n is the number of existing wells within a 10-mile radius of maternal residence in the birth year.
The IDW well count was calculated for each maternal residence with ≥ 1 gas wells within 10 miles. The final distribution then was divided into tertiles (low, medium, and high) for subsequent logistic and linear regression analysis. Each tertile was compared with the referent group (no natural gas wells within 10 miles, IDW well count = 0).
Statistical analysis. We used logistic regressions to study associations between each dichotomous outcome and IDW exposure group. We also considered term birth weight as a continuous outcome using multiple linear regression. First, we estimated the crude odds ratio (OR) associated with IDW exposure tertile for each binary outcome, followed by a Cochran–Armitage test to evaluate linear trends in binominal proportions with increasing IDW exposure (none, low, medium, and high). We further investigated associations by adjusting for potential confounders, as well as infant and maternal covariates selected based on both a priori knowledge and empirical consideration of their association with exposure and an outcome. Specifically, covariates in our analysis of all outcomes except outcomes with very few events (i.e., NTDs, conotruncal defects, EMDs, and TVDs) included maternal age, education (< 12, 12, 13–15, ≥ 16 years), tobacco use (smoker, nonsmoker), ethnicity (Hispanic, non-Hispanic white), and alcohol use (yes, no), as well as parity at time of pregnancy (0, 1, 2, > 2) and infant sex. Gestational age was also included in the analysis of term birth weight. Elevation of maternal residence also was considered in the analysis because most wells are < 7,000 feet, and elevation has been associated with both preterm birth and low birth weight (Niermeyer et al. 2009 (link)). For 272 births where elevation of maternal residence was missing, elevation was imputed using mean elevation for maternal ZIP code. For outcomes with very few events, only elevation was included in the multiple logistic modeling to avoid unstable estimates. The ORs and their 95% CIs were used to approximate relative risks for each outcome associated with IDW count exposure tertile (low, medium, and high) compared with no wells within 10 miles, which is reasonable because of the rarity of the outcomes. We considered the statistical significance of the association, as well as the trend, in evaluating results, at an alpha of 0.05. We evaluated the confounding potential of the 1998 introduction of folic acid fortification on the birth defect outcomes and found only a decrease in NTD prevalence after 1998 (see Supplemental Material, Table S1).
In a sensitivity analyses, we explored reducing exposure to 2- and 5-mile buffers around the maternal residence, as well as restricting the cohort to births occurring between 2000 and 2009 to exclude births before the expansion of NGD. We report estimated associations with 95% CIs. All statistical analyses were conducted using SAS® software version 9.3 (SAS Institute Inc., Cary, NC).
Publication 2014
Study population. The NBDPS recruits cases from population-based, active surveillance congenital anomaly registries in nine U.S. states and includes live births and stillbirths > 20 weeks gestation or at least 500 g, as well as elective terminations of prenatally diagnosed defects when available (Yoon et al. 2001 (link)). Arkansas, Iowa, and Massachusetts ascertain cases statewide, whereas California, Georgia, New York, North Carolina, Texas, and Utah ascertain cases in select counties. Cases are reviewed by clinical geneticists using standardized study protocols to determine study eligibility and classification, and cases with chromosomal/microdeletion disorders and disorders of known single-gene deletion causation are excluded. Controls are unaffected livebirths who are randomly selected from vital records or hospital records, depending upon study center. The NBDPS has been approved by the institutional review boards (IRBs) of all participating centers, and all participants provided written or oral informed consent before participation. These analyses were reviewed and approved by the University of North Carolina IRB.
For this analysis, the study population consisted of all controls and eligible cases with a simple, isolated CHD (i.e., a single CHD with no extra-cardiac birth defects present) and an estimated date of delivery (i.e., due date) from 1 October 1997 through 31 December 2006. During this time period, the participation response was 69% among all cases and 65% for controls. Within the NBDPS, a team of clinicians with expertise in pediatric cardiology reviewed information abstracted from the medical record and centrally assigned a single, detailed cardiac phenotype to each case whose diagnosis was confirmed by echocardiography, cardiac catheterization, surgery, or autopsy and documented in the medical record. Phenotypes were then aggregated into individual CHDs and defect groupings (Botto et al. 2007 (link)). The following additional groups were created because of limited sample size of individual defects: a) other conotruncal defects, which included common truncus, interrupted aortic arch–type B (IAA-type B), interrupted aortic arch–not otherwise specified (IAA-NOS), double outlet right ventricle associated with transposition of the great arteries (DORV-TGA) and not associated with TGA (DORV-other), and conoventricular septal defects (VSD-conoventricular); and b) atresias that included both pulmonary and tricuspid atresia. Simple, isolated CHD cases represented 64% (n = 12,383) of the total CHD cases. We restricted the analysis to offspring with a single CHD to create more etiologically homogeneous case groups, although this limits the generalizability of our findings. Women who reported having pregestational diabetes (types 1 and 2) during their pregnancy were excluded owing to the established association with CHD (Correa et al. 2008 ). Women living > 50 km from a pollutant-specific air monitor were excluded from that analysis.
Exposure assignment. Each woman reported the due date that was provided by her clinician during pregnancy to obtain the gestational age of the infant at birth. Using the gestational age to estimate the date of conception, we assigned calendar dates to each week of pregnancy. Women’s residential addresses during pregnancy were centrally geocoded to ensure consistency across study centers. Each geocoded address during weeks 2–8 of pregnancy was matched to the closest air monitor for each pollutant, with > 50% of the data available using ArcGISv10 (ESRI, Redlands, CA) and monitor locations obtained from U.S. EPA’s Air Quality System (U.S. EPA 2013 ). Participants from 1996–1998 were excluded from the analysis of PM2.5 because monitoring began in 1999.
We used the daily maximum hourly measurement for CO, NO2, and SO2, the daily maximum 8-hr average for O3, and 24-hr measurements of PM10 and PM2.5 to assign exposure. We averaged over the daily maximum or 24-hr measurements for weeks 2–8 of pregnancy to assign a 7-week and also 1-week averages of the daily values. We included week 2 in addition to the standard window of cardiac development, because of the potential for lag effects of air pollution (van den Hooven et al. 2012 (link)). If only a single measurement was taken during a given week, it was assigned as the weekly exposure. Ambient levels of each pollutant except O3 were categorized into the following categories, using the distribution of pollutant concentration among controls: less than the 10th centile (referent), 10th centile to less than the median, the median to less than the 90th centile, and greater than or equal to the 90th centile. These categories captured the departure from linearity observed in initial, exploratory analyses (data not shown). For similar reasons, O3 was categorized into quartiles. Centiles were calculated separately for the 7-week and 1-week measures of exposure.
Statistical analysis. The following variables obtained from the maternal interview were identified as potential confounders through directed acyclic graph analysis (Greenland et al. 1999 (link)) and included in the final adjustment set: maternal age, race/ethnicity, educational attainment, household income, tobacco smoking in the first month of pregnancy, alcohol consumption during the first trimester, and maternal nativity. Maternal age was represented as a single, continuous term, measured at the time of conception. Race/ethnicity was self-reported and categorized into the following groups: white non-Latino, black non-Latino, Latino, Asian or Pacific Islander, and other. Educational attainment was collapsed into six categories: 0–6 years of education, 7–11 years, high school graduate or equivalency, 1–3 years of college or trade school, 4 years of college or completion of a bachelor’s degree, and an advanced degree. Household income was self-reported as < $10,000 annually, > $50,000 annually, or in-between. We adjusted for any tobacco use in the first month of pregnancy and differentiated between some alcohol consumption (less than four drinks) and binge drinking (four or more drinks) during the first trimester. Maternal nativity was defined as self-report of being born outside the United States.
To account for potential differences in case ascertainment by study center, models were also adjusted for the center-specific ratio of septal defects to total CHDs. Identifying septal defects often depends on method of case ascertainment (Martin et al. 1989 (link)). All potential confounders, as well as distance to major roadway, prepregnancy body mass index (BMI), and maternal occupation status during pregnancy were assessed for effect measure modification by constructing logistic regression models with and without interaction terms and conducting likelihood ratio tests using an a priori alpha level of 0.1. Distance to the closest major road—defined as an interstate, U.S. highway, state, or larger county highway—was constructed using ArcGISv10 and then dichotomized at 50 m. Prepregnancy BMI was defined using self-reported maternal height and weight and categorized according to National Institutes of Health (1998) guidelines into underweight (BMI < 18.5), normal weight (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30), and obese (BMI ≥ 30). Maternal occupation status was defined as ever working outside the home during any time during pregnancy.
For each pollutant, models were constructed to explore individual defects and defect-groupings. If a woman did not have at least one monitoring value for each week of exposure, she was excluded from the weekly analysis. We explored the relationships between all weeks and all defects because of uncertainty in pregnancy dating when using an estimated date of conception and the lack of clearly elucidated mechanisms by which cardiac development could be disrupted by exposure to air pollution. Animal research suggests that exposures outside the typical period of development for an individual heart structure could also be etiologically relevant (Morgan et al. 2008 (link)).
Because we simultaneously assessed multiple weeks of exposure and multiple defects/groupings, we constructed two-stage hierarchical regression models to account for the correlation between estimates and partially address multiple inference (Greenland 1992 (link); Witte et al. 1998 (link)). The first-stage, represented in Equation 1, was an unconditional, polytomous logistic regression model of individual CHDs on exposure (x) defined as either all 1-week averages of maximum or 24-hr pollutant values or the single 7-week average, and the full adjustment set (w) detailed above.
bd is the vector of regression coefficients corresponding to pollutant exposure for an individual CHD (d), cd is the vector of regression coefficients corresponding to the covariates for a given defect, and m is the total number of individual types of CHDs. The second-stage model, which defines how the first-stage betas are associated, is given in Equation 2:
βi = Zir + δi, [2]
where Zi is a row in the design matrix that includes an intercept term and then indicator variables for type of defect, broader defect grouping, and exposure week/level for the ith β, r is the vector of coefficients corresponding to the variables included in the design matrix, and δi are independent normal random variables with a mean of zero and a variance of τ2 that describe the residual variation in βi. The obtained second-stage coefficients, r, are used to estimate values toward which the first-stage coefficients will be shrunk, with the magnitude of the shrinkage depending on the precision of the maximum-likelihood estimate obtained in stage 1 and the value of the second-stage variance, τ2 (Greenland 1992 (link); Witte et al. 1998 (link)). We fixed τ2 at 0.5, corresponding to a prior belief with 95% certainty that the residual odds ratio (OR) will fall within a 16-fold span.
To assess whether our results were robust to changes in model specification, we conducted sensitivity analyses by setting the value of τ2 to 0.25, corresponding to a 7-fold OR span, as well as to a value of 1, corresponding to a 50-fold span. We also explored different specifications for the design matrix, in turn defining the prior value as a common mean for all defects, a common mean for each defect, or a common mean for each exposure week/level, across defects. Individual defects with > 10 but < 100 cases were excluded from hierarchical models and explored using Firth’s penalized maximum-likelihood method to address the quasi-complete separation that occurred due to small sample size (Heinze and Schemper 2002 (link)). These defects included the individual defects collapsed into the other conotruncals and atresia categories described above; Ebstein’s anomaly, which was part of the right ventricular outflow tract obstruction (RVOTO) defect grouping; and muscular ventricular septal defects (VSDmuscular), which was part of the septal defect-grouping. IAA-type A and partial anomalous pulmonary venous return had < 10 cases each and were excluded from all individual analyses, but were included in the left ventricular outflow tract obstruction (LVOTO) and anomalous pulmonary venous return (APVR) defect groupings, respectively. To assess whether pollutant–defect relationships conformed to a monotonic dose response, we reanalyzed the data using incremental coding which compares each category of exposure to its immediate predecessor. If the incremental ORs are all above (or below) 1, the relationship conforms to a monotonic dose response (Maclure and Greenland 1992 (link)).
To explore associations with CHDs within a multipollutant context, a principal component analysis (PCA) was conducted among participants who lived within 50 km of each type of monitor. PCA is used to reduce the number of correlated variables into a smaller number of artificial variables that capture most of the variance of the original variables while being uncorrelated with each other (Hatcher 1994 ). This allows the resulting factors to be included within the same model, reducing issues of multicollinearity. Applying PCA, we retained components that accounted for at least the same or more variance than one of the original pollutant variables. We then applied a varimax rotation and calculated factor scores for each participant. These factor scores were categorized using the 10th, 50th, and 90th centiles and used to assign exposure in hierarchical models.
Publication 2014
The study was a randomized, double-blind, placebo-controlled trial conducted by the Pediatric Heart Network comparing the effects of enalapril with those of placebo in infants with single ventricle.18 (link), 19 (link) Patients were enrolled from August, 2003, through May, 2007, at 10 centers in the United States and Canada. A detailed description of the study design and quality assurance methods for anthropometric measurement has been published.19 (link) In brief, inclusion criteria consisted of age ≤ 45 days, age > 1 week if born at 35 weeks gestation, presence of single ventricle physiology, stable systemic and pulmonary blood flow, and planned SCPC surgery. Exclusion criteria included anatomic diagnosis of pulmonary atresia with intact ventricular septum, < 3 days after palliative cardiac surgical procedure (if performed), aortic oxygen saturation < 65%, current mechanical ventilatory or intravenous inotropic support, creatinine >1.0 mg/dL, absolute neutrophil count <1000 cells/mL, chromosomal or recognizable phenotypic syndrome of non-cardiac congenital abnormalities associated with growth failure, and prior ACE inhibitor use for > 7 consecutive days. The protocol was approved by the institutional review boards at the participating institutions, and written informed consent was obtained from the parent or guardian of each patient.
The primary outcome was weight-for-age z-score at 14 months of age. Patients were followed until 14 months of age to allow assessment of the effects of ACE inhibitor therapy for at least 6 months after the volume-unloading that occurs after the SCPC surgery. Secondary endpoints included other measures of somatic growth, Ross heart failure class20 (link), brain natriuretic peptide (BNP) concentration, ventricular geometry and function obtained by two-dimensional echocardiography, and neurodevelopmental and functional status. Echocardiograms were analyzed centrally by a single core laboratory observer. The methods used for measuring ventricular volumes and assessment of intraobserver variability in single ventricle patients have been detailed previously.21 (link) In brief, echocardiogaphic images were analyzed from the apical (ventricular long-axis) and parasternal short-axis views. The endocardial border of the single ventricle was traced at end-diastole and end-systole and the epicardial border was traced at end-diastole in both planes. End-diastolic volume, end-systolic volume, and mass were calculated using a biplane-modified Simpson’s rule. The EF was calculated as (end-diastolic volume − end-systolic volume)/end-diastolic volume. Ventricular mass was calculated as myocardial end-diastolic volume (epicardial volume − endocardial volume) × myocardial density (1.05 g/ml). Echocardiographic measurements and derived indexes were expressed as z-scores relative to body surface area (BSA) or age in normal children.22 (link) BNP concentration was analyzed centrally. Endpoints were measured at the study visit performed immediately prior to the SCPC surgery (mean age 5.1±1.8 months) and at the final study visit (mean age 14.1±0.9 months).
Patients were randomly assigned in a 1:1 ratio to the enalapril and placebo treatment groups using randomly permuted blocks within strata defined by the presence or absence of hypoplastic left heart syndrome, with dynamic balancing within center. The initial enalapril dose was 0.1 mg/kg/day. Medication was uptitrated as tolerated over a period of two weeks to the target dose of 0.4 mg/kg/day given in two divided doses. The dose of study drug was adjusted for weight gain.
Adverse events were classified as non-serious, moderately serious and serious using the Common Terminology Criteria for Adverse Event v.3.0 categories23 and compared between groups. All serious adverse events were adjudicated by an independent physician who was unaware of treatment group assignment.
Publication 2010

Most recents protocols related to «Atresia»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2024
One hundred and ten patients underwent surgery for congenital intestinal atresia or stenosis, including gastric and duodenal atresia/stenosis, at our hospital from January 1990 to June 2022. Among them, 30 patients had CIA-I/S. Two patients with multiple atresia and two patients whose postoperative course details were uncertain were excluded from this study. Twenty-six patients with CIA-I/S were then divided into 3 groups according to the surgical procedure: Group A, web excision with a pre-membranous incision of the dilated intestine proximal to the atresia (n = 14); Group B, enteroplasty of a trans-membranous vertical incision (n = 7); and Group C, diamond-shaped anastomosis (n = 5). No significant difference was found among the 3 groups in patient demographic information (Table 1). The trans anastomotic tube (TAT) was placed in 7 patients: 4, 2, and 1 in Groups A, B, and C, respectively. We retrospectively compared several clinical parameters related to the surgical procedure and the postoperative course among the 3 groups.
Publication 2024
Clinical data including age, sex, premature birth (<37 weeks’ gestational age), birth weight, mode of delivery, intrauterine infection, blood transfusion within 48 hours before NEC, patent ductus arteriosus (PDA), patent foramen ovale, preoperative sepsis, pathological and anatomical classification of intestinal atresia, postoperative feeding, duration of NEC recurrence after the operation, treatment method, and prognosis were collected. Laboratory examinations including routine blood analysis, C reactive protein analysis, X-ray, and abdominal CT were performed when abdominal distension, bloody stools, and infection indicators appeared.
The diagnostic criteria for postoperative NEC were as follows: Bell stage II or above with at least one or more gastrointestinal symptoms, such as bilious emesis or gastric aspirate; blood in the stool without a rectal fissure; abdominal distension; and at least one radiographic sign, such as pneumatosis intestinalis, pneumoperitoneum, or hepatobiliary gas.5 (link) Patients suspected of having NEC were excluded.
Proximal jejunal atresia (PJA) was defined as jejunal atresia within 10 cm of the Treitz ligament, while non-PJA referred to atresia located 10 cm away from the Treitz ligament. Pathological classification of JIA includes type I, type II, type IIIA, type IIIB, and type IV, as previously reported.2 6 (link)
Publication 2024
Complex JIA was defined as any neonate with Type 2, Type 3, or Type 4 JIA. Any neonate with a diagnosis of Type 1 JIA or who had an undesignated type but underwent a web excision, the standard surgical approach to Type 1 JIA, was excluded from our study. We also excluded all neonates with an undesignated JIA type and unspecified surgical procedure. All those with concomitant gastrointestinal anomalies, including duodenal atresia, colonic atresia, or gastroschisis, were excluded. Lastly, any neonate with suspected JIA who expired before surgical intervention was excluded.
Publication 2024
In addition, we focused on 17 patients with duodenal atresia/stenosis to eliminate the effect of different sites of obstruction on outcomes. Similarly, 17 patients were then divided into 3 groups: Group D-A, web excision with a pre-membranous incision of the dilated intestine proximal to the atresia (n = 6); Group D-B, enteroplasty of a trans-membranous vertical incision (n = 6); and Group D-C, diamond-shaped anastomosis (n = 5). TAT was placed in 4 patients: 1, 2, and 1 in Groups D-A, D-B and D-C, respectively. There was no significant difference among the subgroups in patient demographic information (Table 2).
Publication 2024

Top products related to «Atresia»

Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.
Sourced in Germany, United States, United Kingdom, Netherlands, Spain, Japan, Canada, France, China, Australia, Italy, Switzerland, Sweden, Belgium, Denmark, India, Jamaica, Singapore, Poland, Lithuania, Brazil, New Zealand, Austria, Hong Kong, Portugal, Romania, Cameroon, Norway
The RNeasy Mini Kit is a laboratory equipment designed for the purification of total RNA from a variety of sample types, including animal cells, tissues, and other biological materials. The kit utilizes a silica-based membrane technology to selectively bind and isolate RNA molecules, allowing for efficient extraction and recovery of high-quality RNA.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, Japan, United Kingdom, Austria, Canada, Germany, Poland, Belgium, Lao People's Democratic Republic, China, Switzerland, Sweden, Finland, Spain, France
GraphPad Prism 7 is a data analysis and graphing software. It provides tools for data organization, curve fitting, statistical analysis, and visualization. Prism 7 supports a variety of data types and file formats, enabling users to create high-quality scientific graphs and publications.
Sourced in France, United States
FibroScan is a non-invasive diagnostic device that uses vibration-controlled transient elastography (VCTE) technology to measure liver stiffness. The device transmits a mild vibration through the skin and measures the velocity of the resulting shear wave, which is directly related to the stiffness of the liver tissue. This information can be used to assess the degree of liver fibrosis.
Sourced in United States, Germany, Canada, China, France, United Kingdom, Japan, Netherlands, Italy, Spain, Australia, Belgium, Denmark, Switzerland, Singapore, Sweden, Ireland, Lithuania, Austria, Poland, Morocco, Hong Kong, India
The Agilent 2100 Bioanalyzer is a lab instrument that provides automated analysis of DNA, RNA, and protein samples. It uses microfluidic technology to separate and detect these biomolecules with high sensitivity and resolution.
Sourced in United States, Germany, United Kingdom, Israel, Canada, Austria, Belgium, Poland, Lao People's Democratic Republic, Japan, China, France, Brazil, New Zealand, Switzerland, Sweden, Australia
GraphPad Prism 5 is a data analysis and graphing software. It provides tools for data organization, statistical analysis, and visual representation of results.
Sourced in Germany, United States, Spain, United Kingdom, Japan, Netherlands, France, China, Canada, Italy, Australia, Switzerland, India, Brazil, Norway
The QIAamp DNA Blood Mini Kit is a laboratory equipment designed for the extraction and purification of genomic DNA from small volumes of whole blood, buffy coat, plasma, or serum samples. It utilizes a silica-based membrane technology to efficiently capture and wash DNA, while removing contaminants and inhibitors.
Sourced in United States, Japan, China, Germany, United Kingdom, Switzerland, Canada, Singapore, Italy, France, Belgium, Denmark, Spain, Netherlands, Lithuania, Estonia, Sweden, Brazil, Australia, South Africa, Portugal, Morocco
The StepOnePlus Real-Time PCR System is a compact, flexible, and easy-to-use instrument designed for real-time PCR analysis. It can be used to detect and quantify nucleic acid sequences.

More about "Atresia"

Atresia is a medical condition characterized by the complete closure or absence of a normal body opening or passage.
This congenital abnormality can occur in various parts of the body, such as the esophagus, anus, or bile ducts.
Understanding the mechanisms and characteristics of atresia is crucial for developing effective diagnostic and treatment strategies to improve patient outcomes.
One of the key techniques used in atresia research is the use of TRIzol reagent, a powerful solution for the isolation and purification of RNA from biological samples.
Additionally, the RNeasy Mini Kit, a popular RNA extraction method, can be employed to obtain high-quality RNA for further analysis.
The addition of fetal bovine serum (FBS) to cell culture media is also a common practice in atresia studies, as it provides essential nutrients and growth factors for cell growth and proliferation.
To analyze the data collected during atresia research, scientists often utilize statistical software like GraphPad Prism 7, which offers a wide range of tools for data visualization and analysis.
For the assessment of liver fibrosis, a technique called FibroScan may be employed, which uses ultrasound technology to measure liver stiffness.
The Agilent 2100 Bioanalyzer is another important tool used in atresia research, as it allows for the evaluation of the quality and integrity of RNA samples.
In some cases, researchers may also use the earlier version of GraphPad Prism, known as GraphPad Prism 5, for data analysis and visualization.
When it comes to DNA extraction, the QIAamp DNA Blood Mini Kit is a popular choice, as it provides a simple and efficient method for isolating high-quality genomic DNA from blood samples.
The StepOnePlus Real-Time PCR System is another valuable tool in atresia research, enabling the quantification of gene expression levels using real-time PCR technology.
PubCompare.ai, the leading AI platform, can optimize your atresia research by helping you easily locate the best protocols from literature, pre-prints, and patents using AI-driven comparisons to enhance reproducibility and accuaracy.
PubCompare.ai is your go-to tool for streamlining your atresia research process.